← Back to Search

Vaccine

BCG Vaccinations for Type 1 Diabetes in Children

Phase 2
Recruiting
Led By Denise L Faustman, MD, PhD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Ongoing daily treatment with insulin prior to the screening visit
Presence of one or more of the following: antibodies to glutamic acid decarboxylase (GAD), islet cell autoantibody (ICA), protein tyrosine phosphatase-like protein antibodies (IA-2), Insulin autoantibodies (IAA), zinc transporter 8 antibodies (ZnT8)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1, 2, 3, 4, and 5 years after initial bcg/placebo injection
Awards & highlights

Study Summary

This trial will look at if repeat BCG shots could help treat Type 1 diabetes in kids.

Who is the study for?
Children aged 8 to less than 18 with new onset Type 1 diabetes, diagnosed between 3-12 months ago. They must not have HIV, TB, or be pregnant and should have normal blood tests except for mild creatinine elevation. Participants need to be able to monitor their glucose levels and commit to the study protocol.Check my eligibility
What is being tested?
The trial is testing whether repeated vaccinations with Bacillus Calmette-Guérin (BCG) can positively affect the immune system and metabolism in children who recently developed Type 1 diabetes.See study design
What are the potential side effects?
Possible side effects of BCG vaccination include soreness at injection site, low-grade fever, and swelling of lymph nodes near the injection area. Rarely, more serious reactions like an abscess or bone inflammation could occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been using insulin daily before my screening visit.
Select...
I have antibodies indicating an autoimmune response related to diabetes.
Select...
I am between 8 and 17 years old.
Select...
My blood tests are normal, except for a slight increase in creatinine.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1, 2, 3, 4, and 5 years after initial bcg/placebo injection
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1, 2, 3, 4, and 5 years after initial bcg/placebo injection for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in HbA1c values
Secondary outcome measures
Change in C-peptide
Change in insulin usage
Other outcome measures
Exploratory: Change in hypoglycemia

Side effects data

From 2015 Phase 4 trial • 4262 Patients • NCT01694108
10%
BCG-vaccine related event
3%
Other than dead
1%
Other than BCG-vaccine related
100%
80%
60%
40%
20%
0%
Study treatment Arm
BCG-vaccine
Control Children (no Intervention)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Bacillus Calmette-GuérinExperimental Treatment1 Intervention
2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
Group II: Saline InjectionPlacebo Group1 Intervention
2 placebo injections spaced 4 weeks apart at the beginning of the trial

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,946 Previous Clinical Trials
13,204,528 Total Patients Enrolled
10 Trials studying Diabetes
268,276 Patients Enrolled for Diabetes
Denise L Faustman, MD, PhDPrincipal InvestigatorMassachusetts General Hospital
2 Previous Clinical Trials
300 Total Patients Enrolled

Media Library

Bacillus Calmette-Guérin (Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT05866536 — Phase 2
Diabetes Research Study Groups: Bacillus Calmette-Guérin, Saline Injection
Diabetes Clinical Trial 2023: Bacillus Calmette-Guérin Highlights & Side Effects. Trial Name: NCT05866536 — Phase 2
Bacillus Calmette-Guérin (Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05866536 — Phase 2
~67 spots leftby May 2028